Chemotherapy pill plus radiation for esophageal cancer in older adults
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of a chemotherapy pill (TAS-102) and radiation therapy for older adults with a specific type of esophageal cancer. The goal is to see if this combination is safe and effective for patients who cannot or choose not to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your esophageal cancer must be a type called squamous cell carcinoma, confirmed by biopsy.
- You must be between 65 and 85 years old.
- Your cancer must be at a stage where it is locally advanced (stages IIB to IVB), but not spread to other organs far away.
- You should be able to manage your daily activities with minimal help.
- You must not have had prior chemotherapy, radiation, or surgery for your esophageal cancer.
- Your organs (bone marrow, liver, kidneys, lungs) must be functioning well enough to handle the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach before surgery: a short course of radiation (5 treatments) combined with chemotherapy and immunotherapy. The goal is to shrink the tumor and increase the chance of successful removal, while hopefully reducing side effects and improving long-term outcomes.
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
This trial tests a new combination of chemotherapy drugs and radiation for advanced esophageal cancer that cannot be removed with surgery. The goal is to see if this treatment can help shrink the cancer and improve outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy or radiation for older adults with advanced or recurrent esophageal cancer. The goal is to see if this combination is safe and effective in treating the cancer and possibly slowing its growth.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.